HTAtlas
← Back to explore

Strong-Oakley nonparametric regression EVSI method

Methodpeer-reviewed✓ Source-grounded

A fast method to estimate how much value collecting new data would bring in a health technology assessment, without needing complex simulations.

At a glance

Use when

Estimating EVSI quickly from existing PSA results, when 2-level Monte Carlo is too slow or infeasible, or when posterior sampling is difficult

Avoid when

The data-generating process is intractable, or when the regression relationship between parameters and net benefits is highly nonlinear or unstable

Inputs

Probabilistic sensitivity analysis sample (parameter draws and corresponding net benefits), ability to simulate data sets

Outputs

Per-patient expected value of sample information (EVSI)

How it works

A nonparametric regression-based method for estimating per-patient expected value of sample information (EVSI) using only the probabilistic sensitivity analysis sample. It avoids the computationally intensive 2-level Monte Carlo procedure by regressing net benefits on sampled parameter values, enabling efficient EVSI estimation without re-sampling posteriors or re-running the model.

HTA domains
Clinical Effectiveness, Costs & Economic Evaluation, Aspects Beyond HTA
Assumptions
The probabilistic sensitivity analysis sample is representative of the joint parameter distribution; the relationship between parameters and net benefits can be captured via regression; data can be simulated under the proposed study design
Strengths
Computationally efficient, avoids inner Monte Carlo loop, works with any model complexity and parameter distribution, uses existing PSA outputs
Limitations
Relies on quality of regression fit; requires ability to simulate data; accuracy depends on sample size and regression method choice
Also known as
Regression-based EVSI method, Strong and Oakley method

Questions this answers

References & sources

Similar by meaning

Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.